- Conditions
- Kidney Transplantation
- Interventions
- C1 Esterase Inhibitor, Placebos
- Drug
- Lead sponsor
- Stanley Jordan, MD
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 50
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hereditary Angioedema
- Interventions
- Ruconest
- Biological
- Lead sponsor
- Bernstein Clinical Research Center
- Other
- Eligibility
- 14 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Cincinnati, Ohio
- Conditions
- Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
- Interventions
- Deucrictibant, Placebo
- Drug
- Lead sponsor
- Pharvaris Netherlands B.V.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- San Diego, California • Walnut Creek, California • St Louis, Missouri + 1 more
- Conditions
- Hereditary Angioedema
- Interventions
- CINRYZE with rHuPH20
- Biological
- Lead sponsor
- Shire
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Walnut Creek, California • Atlanta, Georgia + 1 more
- Conditions
- Angioedema
- Interventions
- Lanadelumab
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 12 more
- Conditions
- Hereditary Angioedema (HAE), Angioedema
- Interventions
- Lanadelumab 150 mg, Lanadelumab 300 mg
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 2 Years and older
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Santa Monica, California • Walnut Creek, California + 10 more
- Conditions
- Includes: Hereditary Angioedema
- Interventions
- Berinert® (C1 Esterase Inhibitor)
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- Not listed
- Enrollment
- 318 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 34
- States / cities
- Scottsdale, Arizona • Granada Hills, California • Los Angeles, California + 31 more
- Conditions
- Hereditary Angioedema
- Interventions
- C1 esterase inhibitor [human] (C1INH-nf), Placebo (saline)
- Biological · Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 37
- States / cities
- Hoover, Alabama • Scottsdale, Arizona • Los Angeles, California + 34 more
- Conditions
- Confirmed Coronavirus Disease
- Interventions
- Ruconest
- Drug
- Lead sponsor
- Pharming Technologies B.V.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 4
- States / cities
- Marlton, New Jersey • Mount Holly, New Jersey • Ridgewood, New Jersey + 1 more
- Conditions
- Hereditary Angioedema
- Interventions
- rhC1INH
- Drug
- Lead sponsor
- Pharming Technologies B.V.
- Industry
- Eligibility
- 2 Years to 13 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Hereditary Angioedema
- Interventions
- C1 Esterase Inhibitor, Placebo
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 17
- States / cities
- Granada Hills, California • Weston, Florida • Atlanta, Georgia + 14 more
- Conditions
- Graft Rejection, Kidney Transplantation
- Interventions
- plasmapheresis and IVIG, recombinant C1 inhibitor
- Procedure · Drug
- Lead sponsor
- Pharming Technologies B.V.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency
- Interventions
- Deucrictibant low dose, Deucrictibant high dose, Placebo
- Drug
- Lead sponsor
- Pharvaris Netherlands B.V.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Paradise Valley, Arizona • St Louis, Missouri
- Conditions
- Angioedema
- Interventions
- Icatibant, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- CVI - Common Variable Immunodeficiency
- Interventions
- C1-esterase inhibitor [recombinant] (C1-INH-R)
- Biological
- Lead sponsor
- IMMUNOe Research Centers
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Centennial, Colorado
- Conditions
- End Stage Renal Disease, Chronic Kidney Diseases
- Interventions
- Berinert, Placebo
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency
- Interventions
- Deucrictibant, Placebo
- Drug
- Lead sponsor
- Pharvaris Netherlands B.V.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Paradise Valley, Arizona • San Diego, California + 5 more
- Conditions
- Hereditary Angioedema
- Interventions
- rhC1INH, Placebo (Saline)
- Drug
- Lead sponsor
- Pharming Technologies B.V.
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 15
- States / cities
- Scottsdale, Arizona • Granada Hills, California • Los Angeles, California + 12 more
- Conditions
- Antibody-mediated Rejection
- Interventions
- C1-esterase inhibitor, Placebo
- Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 9 more
- Conditions
- Acute Hereditary Angio Edema
- Interventions
- OCTA-C1-INH, Placebo
- Drug · Other
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Centennial, Colorado • Farmington Hills, Michigan • Toledo, Ohio
- Conditions
- Hereditary Angioedema
- Interventions
- C1 esterase inhibitor [human] (C1INH-nf), Placebo (saline)
- Biological · Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • San Diego, California • Walnut Creek, California + 13 more
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- C1 esterase inhibitor [human] liquid, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Santa Monica, California • Walnut Creek, California + 13 more
- Conditions
- Hereditary Angioedema
- Interventions
- CINRYZE
- Biological
- Lead sponsor
- Shire
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Walnut Creek, California • Atlanta, Georgia + 4 more
- Conditions
- Antibody Mediated Rejection of Kidney Transplant
- Interventions
- C1-INH (Berinert)
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York